Chronic Pain in Adults With CP: Causes and What Actually Helps
Researchers themselves have called it perhaps the least understood, least studied comorbidity of CP, despite affecting nearly everyone who lives with it into adulthood, and despite both patients and the NIH specifically naming it a top research priority. This is a genuine attempt to give it the dedicated attention it deserves: the real, distinct mechanisms behind different kinds of pain, why that distinction changes treatment entirely, the genuine impact on quality of life, and an honest look at what the evidence actually says helps.
How common this actually is
A dedicated North American patient registry gathering real, self-reported experiences from adults with CP found the back and weight-bearing joints of the lower extremities reported most frequently as painful, with an average participant age of 43, consistent with the decades-long biomechanical pattern this whole condition follows.
This isn’t a rare or edge-case experience within the CP adult population; it’s genuinely closer to the default. Given how consistently that scope shows up across separate studies and separate data sources, chronic pain deserves to be treated as an expected, routine part of adult CP care planning, discussed proactively at every check-in, rather than something that only comes up if a patient happens to raise it themselves. A simple, direct question at the start of every visit, genuinely asking rather than assuming the answer, costs almost nothing and catches far more than waiting for a complaint to surface unprompted.
The three distinct pain types
Not all CP-related pain is the same kind of pain, and this genuinely matters for how it should be treated. Treating nociplastic pain as though it were purely nociceptive, for instance, focusing entirely on the joint or muscle rather than the nervous system’s own sensitisation, tends to produce disappointing results even when the physical treatment itself is technically sound, simply because it’s addressing the wrong mechanism.
Nociceptive pain
86.3%From actual tissue or joint damage, the type most people assume all CP-related pain is.
Typically described as: sore, achy, tender.
Nociplastic pain
45.8%The nervous system’s own pain processing becomes sensitised, a state researchers call central sensitisation, mechanistically similar to fibromyalgia and genuinely distinct from ongoing tissue damage. This type has historically been poorly recognised in CP specifically, despite being genuinely common.
Neuropathic pain
16.9%From actual nerve involvement, sometimes nerve entrapment related to long-standing contractures, sometimes spinal degeneration compressing a nerve.
Typically described as: sharp, burning, stabbing.
A genuinely useful tool: describing pain using this specific language, rather than a general “it hurts,” helps a provider consider which mechanism is actually involved, since each type points toward a different treatment approach. Many adults experience more than one type simultaneously, which is exactly why a single treatment targeting only one mechanism often falls short on its own.
Nociplastic pain specifically deserves particular attention given how historically under-recognised it’s been. Because it doesn’t correspond to visible tissue damage on imaging or examination, it has sometimes been dismissed entirely, treated as though it weren’t real simply because it doesn’t show up the way nociceptive pain does. The nearly 46% prevalence figure above should put that dismissal to rest directly: this is a genuinely common, genuinely real mechanism, not an exception, and deserves the same clinical seriousness as pain with a visible cause.
Why this distinction matters practically
Consider two adults reporting identical pain intensity on a standard 1-10 scale. One has nociceptive pain from an arthritic hip, genuinely responsive to anti-inflammatory approaches, activity modification, and eventually surgical options if needed. The other has nociplastic pain, their nervous system amplifying signals well beyond what any actual tissue damage would explain, and the same anti-inflammatory or surgical approaches will likely do very little, since there’s no proportional tissue problem to address that way.
A pain score alone can’t distinguish these two people. Only understanding the underlying mechanism, through careful history-taking, examination, and precisely the kind of descriptive language covered above, can. This is genuinely the single most practically useful concept in this entire article: matching the mechanism to the treatment approach, rather than escalating generic pain treatment when the first approach doesn’t work.
In practice, this often means a genuinely different first conversation with a provider than the one many adults with CP are used to having. Instead of “how bad is it, one to ten,” the more useful starting questions look more like: does it feel sharp or achy? Is it worse with movement or present even at rest? Does it come with tingling, numbness, or burning anywhere? The answers to these specific questions do far more diagnostic work than intensity alone ever could.
Common specific sources
Research tracking multiple distinct pain origins in the same individuals commonly identifies the lower back, joint arthritis, connecting directly to the decades of biomechanical loading covered in our premature aging guide, chronic headaches, and irritable bowel-type symptoms. Spinal issues specifically are covered in our guide to scoliosis, and reflux-related discomfort in our GERD guide.
Constipation, covered in its own dedicated guide, is another genuinely common but frequently overlooked source, since abdominal discomfort doesn’t always get connected back to bowel function unless directly asked about. This pattern repeats across nearly every source on this list: the pain itself gets treated as an isolated, mysterious symptom rather than traced back to its actual, often very identifiable origin.
A genuinely practical takeaway from this list: new or worsening pain deserves a real, structured search for its specific source, working systematically through the common candidates above, rather than a general assumption that it’s simply “part of having CP” and therefore not worth investigating further. Nearly every source on this list is independently addressable once correctly identified.
The documented recognition gap
Researchers have described chronic pain as perhaps the least understood, least emphasised, and least studied comorbidity of CP, despite affecting the vast majority of adults living with the condition, a genuinely striking gap given how routinely mobility, communication, and cognition get discussed in CP care compared with pain specifically.
Genuinely worth noting: a community registry analysis found no meaningful difference in average pain severity scores across different GMFCS functional levels, and no meaningful difference by age group either. Separately, pain is reported as more prevalent, not less, among adults with better communication ability, and prevalence doesn’t appear to differ meaningfully by functional severity level. All three findings point toward real under-recognition, not toward pain simply being absent in people who report it less.
The practical implication is genuinely direct: assuming a person with milder CP, or one who communicates easily, is “less likely” to be dealing with significant pain gets the actual data backwards. If anything, the opposite assumption is closer to correct, and providers unfamiliar with this specific research finding may inadvertently under-investigate pain reports from exactly the patients most able to articulate them clearly.
For adults with significant communication differences specifically, this recognition gap compounds further, connecting directly to the broader challenge covered in our guide on assessing pain in nonverbal CP. The absence of a clear verbal complaint has never meant the absence of pain itself; it has only ever meant the absence of the most familiar way of reporting it.
The real impact on quality of life
Adults with chronic pain generally have been found to have lower quality of life than the general population, and even lower than adults living with cancer, heart disease, or diabetes. This isn’t a claim specific to CP alone, but it applies directly, since CP-related chronic pain shares the same fundamental biological and psychological mechanisms as chronic pain from any cause.
Psychosocial factors specifically, pain catastrophising (a tendency to feel overwhelmed or helpless when anticipating or experiencing pain), depression, and a person’s own confidence in managing their pain, have been shown in research on interdisciplinary pain treatment to genuinely predict how much quality of life actually improves with treatment, above and beyond the physical treatment itself. Our guide on depression and anxiety in CP covers this psychological dimension, including its own documented connection to pain specifically, in full.
This isn’t a claim that pain is “psychological” in the dismissive sense some people fear when psychosocial factors get raised in a medical conversation. It’s closer to the opposite: pain is genuinely, measurably a whole-person experience, and treating only the tissue while ignoring how someone thinks about and copes with their pain leaves real, documented ground on the table. A biopsychosocial approach isn’t a lesser alternative to “real” medical treatment; it’s the approach the actual outcomes data supports most strongly.
An honest look at the treatment evidence
Currently, the certainty of evidence for both medication-based and non-medication treatments specifically in adults with CP remains very low to low. This isn’t a reason to give up on treatment entirely; it’s a reason to expect a thoughtful, somewhat individualised approach from your care team rather than one single, universally proven protocol.
This gap is exactly why both patient stakeholder groups and the National Institutes of Health have specifically named improving pain treatment understanding in adult CP a top research priority, not a niche concern. Researchers have also found elevated levels of specific inflammatory pain markers in fluid and tissue samples from people with related degenerative pain conditions, an active area of investigation that may eventually translate into more targeted pharmacological options specifically for CP.
Part of the reason this evidence base remains thin is genuinely practical: adults with CP have historically been under-represented in pain research generally, partly because so much CP research has focused on children, and partly because studying pain across a population as heterogeneous as CP, spanning enormous variation in type, severity, and communication ability, is genuinely methodologically harder than studying a single, more uniform condition. Neither excuse changes the current gap, but both help explain why it exists and why patient-reported registry data, like the source behind several statistics in this article, has become such a valuable stopgap while more rigorous trials catch up.
None of this means treatment should wait for perfect evidence to arrive. Providers experienced with adult CP specifically routinely draw on the broader chronic pain literature, adapting general pain-management principles thoughtfully to the specific mechanical and neurological realities of CP, rather than either ignoring pain entirely or applying generic protocols that don’t account for CP’s particular patterns.
What actually helps
-
Describe pain precisely, not generally Using the specific words above helps match the approach to the actual mechanism involved.
-
Address underlying mechanical contributors Where nociceptive pain is driven by ongoing spasticity or joint loading, structured approaches covered in our physiotherapy guide are genuinely worth discussing.
-
Treat the psychosocial dimension directly, not as an afterthought Given how directly catastrophising, depression, and pain self-efficacy predict outcomes, approaches like cognitive behavioural therapy genuinely belong alongside physical treatment, not after it fails, and specifically not only offered once every physical option has already been exhausted.
-
Seek a genuinely multidisciplinary approach Given the acknowledged evidence gap, a team combining medical, physical, and psychological expertise together tends to outperform any single specialist working in isolation.
-
Track pain patterns over time, not just intensity Noting what makes pain better or worse, and when it occurs relative to activity, sleep, or stress, gives a provider genuinely useful diagnostic information beyond a single number on a scale, and reveals patterns neither of you might notice from memory alone.
Since nociceptive pain, the most common type at 86.3%, often traces directly to spasticity-driven joint loading and abnormal biomechanics, SFDM addresses one of the most common underlying mechanical contributors directly, rather than only managing the resulting pain symptomatically. This won’t address nociplastic or neuropathic pain directly, which is exactly why the multidisciplinary approach above matters, but for the mechanical contributor specifically, it’s a genuine, direct option worth discussing.
Nociceptive pain, the most common type covered in this article, is frequently driven by spasticity-related joint loading. It’s worth finding out directly whether SFDM could address that underlying contributor.
Discuss an SFDM Evaluation →Frequently asked questions
How common is chronic pain in adults with CP?
75-78% experience chronic pain lasting over 3 months; 90% have a pain-related diagnosis at some point; over 70% deal with multiple pain sources at once. Back and weight-bearing joints are most commonly reported.
Are there genuinely different types of pain?
Yes, three: nociceptive (86.3%, tissue/joint damage), nociplastic (45.8%, central sensitisation, fibromyalgia-like), and neuropathic (16.9%, nerve involvement). Many people have more than one simultaneously.
Does pain severity relate to physical severity?
No. No meaningful difference across GMFCS levels or age groups; pain is actually reported more by those with better communication ability, pointing to under-recognition, not absence.
How much does this affect quality of life?
Substantially, lower than the general population and even lower than adults with cancer, heart disease, or diabetes. Catastrophising, depression, and pain self-efficacy genuinely predict treatment outcomes.
Is this actually a research priority?
Yes, formally named a top priority by both patients and the NIH, precisely because current treatment evidence remains very low to low certainty in this specific population.
What actually helps?
Precise pain description, addressing mechanical contributors like spasticity, treating the psychosocial dimension directly (not as an afterthought), and a genuinely multidisciplinary team approach.
References
- “Pain in adults with cerebral palsy: A systematic review.” Developmental Medicine & Child Neurology, Wiley. Wiley ↗
- “Adults with cerebral palsy and chronic pain experience: A cross-sectional analysis of patient-reported outcomes from a novel North American registry.” ScienceDirect. ScienceDirect ↗
- “Pathophysiology of chronic pain in cerebral palsy: implications for pharmacological treatment and research.” Developmental Medicine & Child Neurology, Wiley. Wiley ↗
- “Examining the roles of depression, pain catastrophizing, and self-efficacy in quality of life changes following chronic pain treatment.” PMC. PMC ↗